CVS Health Corporation
NYSE•CVS
CEO: Mr. Roger N. Farah
Sector: Healthcare
Industry: Medical - Healthcare Plans
Listing Date: 1996-11-20
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.
Contact Information
Market Cap
$98.34B
P/E (TTM)
55.5
25.3
Dividend Yield
3.4%
52W High
$85.15
52W Low
$58.35
52W Range
Rank29Top 17.8%
5.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$105.69B+0.00%
4-Quarter Trend
EPS
$2.32+0.00%
4-Quarter Trend
FCF
$2.61B+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Total Revenue Growth Total revenues reached $402.07B USD, marking a 7.8% increase driven by growth across all operating segments.
Health Benefits Premium Growth Health Care Benefits premiums grew 9.7% to $134.75B USD, driven by Medicare Part D impact from Inflation Reduction Act.
Strong Operating Cash Flow Net cash provided by operating activities totaled $10.64B USD, reflecting a 16.8% increase year-over-year from prior performance.
Health Services Revenue Jump Health Services segment revenues increased 9.7% to $190.43B USD, supported by strong PBM solutions and care delivery assets.
Risk Factors
Major Goodwill Impairment Recorded $5.73B USD goodwill impairment charge related to Health Care Delivery unit, severely impacting 2025 operating income.
Operating Income Decline Operating income fell 45.3% to $4.66B USD, primarily due to goodwill charge and $1.22B legacy litigation costs.
Regulatory/Legal Scrutiny Subject to extensive, complex, and changing federal/state laws; compliance efforts require significant ongoing resources and risk penalties.
Cost Forecasting Uncertainty Inability to accurately forecast health care benefit costs, especially due to utilization volatility, risks material adverse impact on margins.
Outlook
Elevated Utilization Expected Utilization levels expected to persist at elevated levels into 2026, potentially pressuring Health Care Benefits segment capacity.
Strategic Exit from Programs Determined to substantially exit ACO REACH and MSSP programs during Q1 2025, recording $288M in associated operating expenses.
Continued Pricing Pressure Expect continued trends of sharing larger rebate portions with clients and facing limited ability to offer retail network differential pricing.
AI Technology Investment Making concerted investments in emerging technology capabilities like Artificial Intelligence to automate and improve operational capabilities enterprise-wide.
Peer Comparison
Revenue (TTM)
$402.07B
$397.96B
$325.78B
Gross Margin (Latest Quarter)
85.6%
70.3%
69.7%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| BMY | $122.85B | 17.4 | 39.3% | 52.4% |
| SNY | $117.05B | 9.4 | 14.7% | 16.0% |
| GSK | $117.01B | 15.1 | 37.2% | 29.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.8%
Moderate Growth
4Q Net Income CAGR
18.3%
Profitability Improved
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Apr 29, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data